In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arbutus Biopharma Corporation

http://arbutusbio.com/

Latest From Arbutus Biopharma Corporation

FTC Tells Medtronic To Sell Intersect ENT Subsidiary To Avoid Monopoly

The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.

Regulation Commercial

Eurofarma Biosimilars Deal Broadens Access To Latin America For Henlius

Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.

Deals Biosimilars

Henlius Speeds Up Efforts On Ophthalmic Bevacizumab

Shanghai Henlius Biotech has revealed the latest update on its proposed ophthalmic version of biosimilar bevacizumab, with a global Phase III trial beginning as the firm also pursues international filings with partner Essex Bio-Technology.

Biosimilars Clinical Trials

Glenmark Follows BeiGene, Nimbus With Early Stage HPK1 Inhibitor

Glenmark is set to initiate a Phase I study for its inhibitor of immuno-oncology target hematopoietic progenitor kinase 1 (HPK1), a segment that has seen increased activity over the recent past with BeiGene, Nimbus and Treadwell Therapeutics among those advancing their molecules.

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Other Names / Subsidiaries
    • Genevant Sciences
    • Inex Pharmaceuticals Corporation
    • OnCore Biopharma, Inc, (Enantigen Therapeutics, Inc.)
    • Tekmira Pharmaceuticals Corporation (TKMR)
    • Protiva Biotherapeutics Inc.
UsernamePublicRestriction

Register